Asundexian

Bayer’s Phase III OCEANIC-STROKE trial showed that asundexian, a Factor XIa inhibitor, significantly reduced the risk of ischemic stroke recurrence when combined with antiplatelet therapy, compared to placebo. Crucially, asundexian did not increase major bleeding events. This marks the first successful Phase III trial for a Factor XIa inhibitor. Bayer plans to pursue marketing authorization globally. Detailed results will be presented at an upcoming scientific congress. Asundexian has received FDA Fast Track designation.